

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Moving things forward in Hodgkin lymphoma | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1786/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1786" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Moving things forward in Hodgkin lymphoma" />
    
            <meta name="og:title" content="F1000Research Article: Moving things forward in Hodgkin lymphoma.">
            <meta name="og:description" content="Read the latest article version by Paul J. Br&ouml;ckelmann, Boris B&ouml;ll, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="17557">
            <meta name="article-id" content="16077">
            <meta name="dc.title" content="Moving things forward in Hodgkin lymphoma">
            <meta name="dc.description" content="Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward.">
            <meta name="dc.subject" content="Hodgkin Lymphoma, chemotherapy, PET, checkpoint inhibition, PD1, PD1-L, CD30, brentuximab vedodin, nivolumab, pembrolizumab, relapsed patients, older patients">
            <meta name="dc.creator" content="Br&ouml;ckelmann, Paul J.">
            <meta name="dc.creator" content="B&ouml;ll, Boris">
            <meta name="dc.date" content="2018/11/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.16077.1">
            <meta name="dc.source" content="F1000Research 2018 7:1786">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Hodgkin Lymphoma">
            <meta name="prism.keyword" content="chemotherapy">
            <meta name="prism.keyword" content="PET">
            <meta name="prism.keyword" content="checkpoint inhibition">
            <meta name="prism.keyword" content="PD1">
            <meta name="prism.keyword" content="PD1-L">
            <meta name="prism.keyword" content="CD30">
            <meta name="prism.keyword" content="brentuximab vedodin">
            <meta name="prism.keyword" content="nivolumab">
            <meta name="prism.keyword" content="pembrolizumab">
            <meta name="prism.keyword" content="relapsed patients">
            <meta name="prism.keyword" content="older patients">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/11/13">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1786">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.16077.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1786">
            <meta name="citation_title" content="Moving things forward in Hodgkin lymphoma">
            <meta name="citation_abstract" content="Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward.">
            <meta name="citation_description" content="Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward.">
            <meta name="citation_keywords" content="Hodgkin Lymphoma, chemotherapy, PET, checkpoint inhibition, PD1, PD1-L, CD30, brentuximab vedodin, nivolumab, pembrolizumab, relapsed patients, older patients">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Paul J. Br&ouml;ckelmann">
            <meta name="citation_author_institution" content="German Hodgkin Study Group and Department I of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany">
            <meta name="citation_author" content="Boris B&ouml;ll">
            <meta name="citation_author_institution" content="German Hodgkin Study Group and Department I of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany">
            <meta name="citation_publication_date" content="2018/11/13">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1786">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.16077.1">
            <meta name="citation_firstpage" content="1786">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1786/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1786.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=17557 /> <input type=hidden id=articleId name=articleId value=16077 /> <input type=hidden id=xmlUrl value="/articles/7-1786/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1786-v1.xml"> <input type=hidden id=article_uuid value=e19c96bb-76fa-401a-8605-33d1526390a8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Moving things forward in Hodgkin lymphoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.16077.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.16077.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1786"
  },
  "headline": "Moving things forward in Hodgkin lymphoma",
  "datePublished": "2018-11-13T14:58:21",
  "dateModified": "2018-11-13T14:58:21",
  "author": [
    {
      "@type": "Person",
      "name": "Paul J. Br&ouml;ckelmann"
    },    {
      "@type": "Person",
      "name": "Boris B&ouml;ll"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1786.html",
            "name": "Moving things forward in Hodgkin lymphoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Moving things forward in Hodgkin lymphoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=17557 data-id=16077 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16077.1" data-recommended="" data-doi="10.12688/f1000research.16077.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1786/v1/pdf?article_uuid=e19c96bb-76fa-401a-8605-33d1526390a8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-16077-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-16077-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-16077-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Brckelmann PJ and Bll B. Moving things forward in Hodgkin lymphoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1786 (<a class=new-orange href="https://doi.org/10.12688/f1000research.16077.1" target=_blank>https://doi.org/10.12688/f1000research.16077.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-16077-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=16077 id=track-article-signin-16077 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16077?target=/articles/7-1786.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17557 /> <input name=articleId type=hidden value=16077 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Moving things forward in Hodgkin lymphoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Paul J. Br&ouml;ckelmann,&nbsp;</span><span class=""><a href="mailto:boris.boell@uk-koeln.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Boris B&ouml;ll</span></a><a href="https://orcid.org/0000-0002-6432-0981" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6432-0981</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Paul J. Br&ouml;ckelmann,&nbsp;</span><span class=""><a href="mailto:boris.boell@uk-koeln.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Boris B&ouml;ll</span></a><a href="http://orcid.org/0000-0002-6432-0981" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6432-0981</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 Nov 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.16077.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> German Hodgkin Study Group and Department I of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany<br/> <p> <div class=margin-bottom> Paul J. Br&ouml;ckelmann <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Boris B&ouml;ll <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=41551-40433></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=41549-40432></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Hodgkin Lymphoma, chemotherapy, PET, checkpoint inhibition, PD1, PD1-L, CD30, brentuximab vedodin, nivolumab, pembrolizumab, relapsed patients, older patients </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Boris B&ouml;ll (<a href="mailto:boris.boell@uk-koeln.de">boris.boell@uk-koeln.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Boris Bll </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> B.B. reports honoraria and research funding from Celgene, MSD, Mundipharma, Johnson & Johnson and Takeda. PJB reports honoraria and research funding by Bristol-Myers Squibb and Takeda </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Brckelmann PJ and Bll B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Brckelmann PJ and Bll B. Moving things forward in Hodgkin lymphoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1786 (<a href="https://doi.org/10.12688/f1000research.16077.1" target=_blank>https://doi.org/10.12688/f1000research.16077.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 Nov 2018, <b>7</b>(F1000 Faculty Rev):1786 (<a href="https://doi.org/10.12688/f1000research.16077.1" target=_blank>https://doi.org/10.12688/f1000research.16077.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 Nov 2018, <b>7</b>(F1000 Faculty Rev):1786 (<a href="https://doi.org/10.12688/f1000research.16077.1" target=_blank>https://doi.org/10.12688/f1000research.16077.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e149>Introduction</h2><p class="" id=d19108e152>Classic Hodgkin lymphoma (HL) is a rather rare cancer of the lymphoid system and clinically presents with swollen lymph nodes or symptoms due to organ involvement of advanced-stage disease. It is one of the most common malignancies in young adults but occurs at all ages. Over the recent decades, a growing incidence in older people between 70 and 80 years of age in addition to the stable peak between 20 and 30 years of age was observed<sup><a href="#ref-1">1</a></sup>. In Western countries, HL occurs at an incidence of 2.5 new cases per 100,000 people per year, resulting in an expected 18,525 cases in Europe annually. Owing to high cure rates with risk-adapted first-line therapy, prevalence is high and an estimated 208,805 people were living with HL in the US in 2015<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d19108e163>Depending on disease extent and presence of constitutional symptoms such as fevers, night sweats, or weight loss, HL is classified as early-stage favorable, early-stage unfavorable, and advanced-stage disease for the purpose of treatment allocation<sup><a href="#ref-3">3</a></sup>. Cure rates with multi-agent chemotherapy and often consolidative radiation therapy (RT) are high with long-term remission rates of 80% to 90%, depending on risk group, age, and treatment<sup><a href="#ref-4">4</a><a href="#ref-7">7</a></sup>. In patients with primary progressive or refractory (1 to 3% of cases, depending on treatment regimen) as well as relapsed disease, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation is administered if feasible and can result in long-term remission in up to 50% of cases<sup><a href="#ref-8">8</a></sup>. More recently, several targeted agents were investigated in this setting and the antibody-drug conjugate brentuximab vedotin (BV) and the checkpoint inhibitors nivolumab and pembrolizumab were approved for relapsed/refractory HL (rrHL)<sup><a href="#ref-9">9</a><a href="#ref-11">11</a></sup>.</p><p class="" id=d19108e188>Despite reductions of intensity of both chemotherapy and RT in recent years, therapy-related short- and long-term morbidity constitutes considerable sequelae and these side effects surmount HL mortality over the years<sup><a href="#ref-12">12</a></sup>. Besides organ damage such as pulmonary or cardiovascular disease as well as infertility, second cancers and long-term fatigue are of particular clinical relevance to patients and caregivers<sup><a href="#ref-13">13</a><a href="#ref-15">15</a></sup>. To minimize these complications, a major goal of current research is to further refine first-line treatment to develop equally effective but less intensive strategies. Ideally, those therapeutic approaches would also be feasible for the growing population of older or frail patients for whom prognosis is less favorable<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>.</p><p class="" id=d19108e209>The present review summarizes recent advances in understanding and the current approach to managing HL. We also address remaining challenges and outline ongoing as well as future efforts to move things forward in HL over the next years.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e215>Hodgkin lymphoma biology</h2><p class="" id=d19108e218>Characterized by a paucity of the malignant Hodgkin and ReedSternberg (HRS) cells in an abundant (micro)environment of immune cells, HL is very distinct from most other cancers and lymphomas<sup><a href="#ref-18">18</a></sup>. The B-cell precursor heritage of HRS cells was long acknowledged, whereas a critical influence of immune checkpoint inhibition via the programmed death 1 (PD1) and PD1-ligand (PD-L1) was only recently reported<sup><a href="#ref-19">19</a></sup>. Owing to amplification or copy gain of 9p24.1<sup><a href="#ref-20">20</a></sup> or mediated by EpsteinBarr virus (EBV) infection<sup><a href="#ref-21">21</a></sup>, HRS cells frequently express PD-L1 and thereby evade a sustained anti-tumor response of the patients immune system. In addition, HRS cells frequently lack major histocompatibility class I (MHC I) expression because of mutations of beta-2-microglobulin (2M)<sup><a href="#ref-22">22</a></sup>. The HL microenvironment is characterized predominantly by T and natural killer cells as well as macrophages, and PD-1 expression occurs in the former<sup><a href="#ref-23">23</a></sup>. The latter are often PD-L1<sup>+</sup> and associated with inferior outcomes with conventional therapies<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. A very recent characterization of tumor-associated T cells via a customized time-of-flight mass cytometry (CyTOF) revealed the presence of PD-1<sup>+</sup> CD4<sup>+</sup> effector and PD-1<sup></sup> CD4<sup>+</sup> regulatory T cells as potential complementary mechanisms of local immunosuppression<sup><a href="#ref-26">26</a></sup>. This rapidly growing understanding of the tumor composition is complemented by the possibility to identify and track cell-free tumor DNA in the blood<sup><a href="#ref-27">27</a></sup>. Although this technique potentially allows non-invasive monitoring of disease activity, it also constitutes the possibility to evaluate the genetic background of HL, which earlier was compromised by the low tumor cell content in biopsies. In summary, recent studies were able to shed light on the distinct biology underlying HL which will help to further develop targeted therapies and synergistic therapeutic concepts.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e280>Recent developments in first-line treatment</h2><div class=section><a name=d19108e283 class=n-a></a><h3 class=section-title>Early-stage disease</h3><p class="" id=d19108e288>Patients with limited stage III disease (that is, involvement of lymph nodes on only one side of the diaphragm and without extra-lymphatic disease) are grouped into early-stage favorable and unfavorable HL for the purpose of first-line therapy. Whereas those with clinical risk factors (RFs) such as involvement of at least three lymphatic areas, an elevated erythrocyte sedimentation rate, extra-nodal (EN) involvement, or a large mediastinal mass (LMM) are considered unfavorable risk, the remaining patients are usually considered a favorable risk group. In contrast to disseminated extra-lymphatic disease, which defines stage IV disease, EN involvement is defined as local limited contiguous tumor spread from a lymphatic HL manifestation. Despite nuances in the RFs used to determine early-stage unfavorable disease, the three major currently applied classifications retain their prognostic impact with conventional treatment<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d19108e295>Already two decades ago, combined modality treatment consisting of two to four cycles of, in most cases, doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy followed by consolidative RT was established for both early-stage risk groups<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. Consecutively, the initially large RT fields could be markedly reduced from subtotal nodal irradiation (STNI) to involved-field (IF-RT) and lately involved-site or -node (IS-/IN-RT) without any loss in efficacy<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. Omission of consolidative RT irrespective of response to chemotherapy results in an impaired disease control, and a recent registry-based analysis reported inferior overall survival (OS)<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Therefore, several randomized trials evaluate the omission of consolidative RT in patients who attain a complete metabolic response<sup>18</sup>F-FDG positron emission tomography (PET) negativitywith systemic therapy.</p><p class="" id=d19108e322>In the UK RAPID trial, PET-negative patients after 3xABVD who did not receive consolidative 30 Gy IF-RT due to randomization into the experimental arm had inferior three-year progression-free survival (PFS) with a three-year OS similar to that of those in the standard arm (per-protocol analysis: 97.1% versus 90.8%)<sup><a href="#ref-35">35</a></sup>. A similar observation was made in the EORTC H10F/U trial. In the experimental arms, patients with early-stage favorable or unfavorable disease received two or four additional cycles of ABVD if PET-negative after 2xABVD instead of one or two additional cycles of ABVD and consolidative 30 Gy IN-RT, respectively. Inferior five-year PFSs of 99.0% versus 87.1% and 92.1% versus 89.6% for patients with favorable and unfavorable early-stage disease (respectively) were reported, whereas until now no differences in OS were reported<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d19108e333>The two large randomized phase III trialsHD16 (early-stage favorable) and HD17 (early-stage unfavorable)evaluating non-inferiority of PET-adapted omission of consolidative RT recently completed recruitment. Of note, PET status is evaluated after completion of systemic therapy with either 2xABVD or 2xABVD + 2xBEACOPP<sub>escalated</sub> in both trials and no further therapy administered in PET-negative patients in contrast to the RAPID or H10 trials. Results are eagerly awaited to inform treating physicians and patients since, to date, omission of RT cannot generally be recommended if optimal disease control is the main goal of therapy. Since differences in three- and five-year PFS are rather small, especially in patients with early-stage unfavorable disease, omission of RT may be considered in individual cases after risks and benefits are weighed. This could apply, for example, to a young female patient with axillary lymph nodes prompting relevant RT volume and dose to healthy breast tissue or to a young man with a family history of cardiac disease requiring relevant RT exposure to his coronary arteries because of lower mediastinal HL involvement.</p><p class="" id=d19108e340>For patients with early-stage favorable HL, a recent long-term analysis confirmed the previously reported favorable outcome with only 2xABVD + 20 Gy consolidative RT<sup><a href="#ref-7">7</a></sup>. In patients with early-stage unfavorable HL, outcome with ABVD-based systemic therapy is less favorable with 10-year PFS of only 84% with 4xABVD + 30 Gy IF-RT, underlining the need for effective therapies in this patient population. Lately, the randomized HD14 trial established a combination of 2xBEACOPP<sub>escalated</sub> + 2xABVD (2+2) as a highly effective approach with five-year PFS of 95.4% in comparison with the standard of 4xABVD (five-year PFS of 89.1%)<sup><a href="#ref-5">5</a></sup>. More recently, the abovementioned H10U trial showed promising five-year PFS of 90.6% with an intensification of therapy by 2xBEACOPP<sub>escalated</sub> for the unfavorable subgroup of interim PET-positive patients after initial 2xABVD<sup><a href="#ref-36">36</a></sup>.</p></div><div class=section><a name=d19108e362 class=n-a></a><h3 class=section-title>Advanced-stage disease</h3><p class="" id=d19108e367>Patients with involvement of lymph nodes on both sides of the diaphragm, disseminated organ, or bone marrow involvement are considered to have advanced-stage disease by all classification systems. Some groups additionally consider patients with stage III disease and a combination of constitutional B symptoms and the RFs of LMM or EN disease (or both) as having advanced-stage disease. Initial treatment in this risk group is guided by an interim PET after two cycles of systemic therapy (PET-2) and consists of up to eight cycles of multi-agent chemotherapy and localized RT to PET-positive residues thereafter.</p><p class="" id=d19108e370>Choice of systemic therapy is a matter of long-lasting and ongoing debate: ABVD is associated with considerably lower acute and long-term toxicity and, in contrast to BEACOPP<sub>escalated</sub>, potentially suitable for patients older than 60 years of age. Long-term toxicities more frequently occurring after BEACOPP-based therapy are sterility and occurrence of second cancers. However, the risks to develop refractory disease or relapse of HL are significantly higher with ABVD, and a recent network meta-analysis confirmed an OS benefit for patients treated with the more intensive regimen<sup><a href="#ref-37">37</a></sup>. To develop individualized approaches, the three recently reported large randomized phase III RATHL, HD18 and AHL2011 trials investigated initial therapy with ABVD or BEACOPP<sub>escalated</sub> guided by interim PET.</p><p class="" id=d19108e383>In the experimental arm of the British RATHL, PET-2negative patients received +4xAVD to avoid bleomycin-associated pulmonary toxicity, and in PET-2positive patients, therapy was intensified by 4xBEACOPP<sup><a href="#ref-38">38</a></sup>. Whereas the de-escalation to AVD proved to be non-inferior in terms of three-year PFS, intensification resulted in three-year PFS of 67.5%. Importantly, escalation was not subject to randomization and only historical comparisons suggest that intensification with BEACOPP<sub>escalated</sub> might be superior to continuation with ABVD in PET-2positive patients. In the GHSG HD18, a de-escalation strategy with patients PET-2negative after 2xBEACOPP<sub>escalated</sub> randomly assigned to receive either +4x or +68xBEACOPP<sub>escalated</sub> was investigated. The experimental strategy was not inferior with five-year PFS of 92.2% versus 90.8% and five-year OS of 97.7% versus 95.4% for the standard approach<sup><a href="#ref-6">6</a></sup>. The French AHL2011 trial recently reported a non-inferior four-year PFS of 87.1% with randomized de-escalation to 4xABVD in patients who achieved a PET-2negative status after 2xBEACOPP<sub>escalated</sub> versus 87.4% with full 6xBEACOPP<sub>escalated</sub><sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d19108e413>Conclusions from across trial comparisons are limited by differences in risk-group definitions, patient populations, and the varying clinical setting and hence are impossible. Nevertheless, it may be concluded from the recent data that PET-2 is an important reliable tool to guide therapy in advanced-stage HL, and one might get the impression that an initial therapy with BEACOPP<sub>escalated</sub> results in long-term outcomes superior to those of ABVD-based strategies.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e423>Drugs beyond conventional chemotherapy</h2><p class="" id=d19108e426>Over many decades, no new drugs were approved for the treatment of HL. That changed in 2011, when the anti-CD30 antibody drug conjugate BV was approved for the treatment of rrHL on the basis of a pivotal phase II trial showing an overall response rate (ORR) of 75% and complete response rate (CRR) of 34%<sup><a href="#ref-10">10</a></sup>. Recent follow-up analyses revealed sustained remissions in patients achieving a CR with five-year PFS of 52%. Interestingly, 9% of all patients maintained a CR even without consolidative stem cell transplantation (SCT)<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d19108e437>To improve efficacy of ABVD in patients with advanced-stage HL, a combination of BV and AVD was investigated in the company-sponsored randomized phase III ECHELON-1 trial: With a superior two-year modified PFS of 82.1% versus 77.1%, 6x BV-AVD was considered superior to 6xABVD, but more mature follow-up or conventional PFS data have not yet been reported and concerns have been expressed over the risk-to-benefit ratio of BV-AVD given the higher toxicity of the novel regimen<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. In patients with early-stage HL, consolidative therapy with BV instead of RT after systemic therapy with ABVD was investigated in a phase II trial and associated with one-year PFS and OS rates of 91% and 95%, respectively, in an early analysis<sup><a href="#ref-43">43</a></sup>. A sequential approach with BV prior to and after AVD in elderly patients with treatment-nave HL was tolerable and resulted in two-year PFS and OS rates of 84% and 93%, respectively<sup><a href="#ref-44">44</a></sup>.</p><p class="" id=d19108e455>More recently, the two checkpoint inhibitors nivolumab and pembrolizumab targeting PD1 on exhausted T and other immune cells were approved for rrHL. Nivolumab and pembrolizumab showed ORRs of 69% and 65%, respectively, and a CRR of 16% with long-lasting responses in patients achieving a partial remission (PR) in the pivotal phase II trials<sup><a href="#ref-9">9</a>,<a href="#ref-11">11</a></sup>. Correlative studies revealed the prognostic relevance of PD-L1 and MHC II expression by HRS cells, shedding light on the mechanisms involved in responses in a heavily pretreated patient population<sup><a href="#ref-45">45</a></sup>. While increased PD-L1 expression was associated with improved PFS, patients with less PD-L1 expression benefited from nivolumab and hence checkpoint inhibition is administered irrespective of the expression profile. Early data of an ongoing trial investigating the combination of nivolumab with BV in rrHL show an ORR of 85% and CRR of 65% while, despite manageable infusion-related reactions, tolerability was good<sup><a href="#ref-46">46</a></sup>. In addition, the first results without relevant follow-up were recently reported for the combination of nivolumab and AVD in advanced-stage HL: Of 51 patients, 90% were able to complete the planned treatment with 4x nivolumab followed by 6x Nivo-AVD, and the ORR was 84% with a CRR of 67% by independent review committee<sup><a href="#ref-47">47</a></sup>.</p><p class="" id=d19108e477>In light of the changing therapeutic landscape, other agents such as bendamustine or lenalidomide experience a revival andsince they proved to be considerably active in rrHL are increasingly used in clinical practice<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. In addition, drugs originally approved for other hematological cancers, such as the histone deacetylase inhibitors panobinstat or mocetinostat or the inhibitor of PI3K idelalisib, have been investigated in rrHL with relevant efficacy and manageable toxicity<sup><a href="#ref-50">50</a><a href="#ref-52">52</a></sup>. A welcomed side effect of the growing armory of effective drugs is the possibility to conduct both autologous and allogeneic SCT increasingly in patients with at least PR, which is associated with a more favorable prognosis<sup><a href="#ref-3">3</a></sup>. Initial reports raised concerns due to toxicity and mortality associated with high-grade graft-versus-host disease associated with allogeneic stem cell transplantation (alloSCT) after reinduction therapy with an anti-PD1<sup><a href="#ref-53">53</a></sup>. More recent data indicate that alloSCT is feasible and associated with high CRR and prolonged remissions. The previously postulated prognostic impact of time between last dose of the anti-PD1 antibody could not be confirmed, and data from larger series are still unavailable<sup><a href="#ref-54">54</a></sup>.</p><p class="" id=d19108e507>Chimeric antigen receptor (CAR) T cells were recently approved for the treatment of other hematologic cancers such as acute lymphoblastic leukemia or B-cell non-HL. Two early-phase trials very recently reported manageable toxicities after infusion of autologous anti-CD30 CAR T cells in patients with rrHL. Investigators from Houston reported two patients with sustained CR (CRR of 29%) and stabilization of disease (SD) in another two of the seven patients treated<sup><a href="#ref-55">55</a></sup>. In a Chinese trial, PR was observed in seven and SD in six among 18 patients treated without any CRs documented yet<sup><a href="#ref-56">56</a></sup>. Aimed at the EBV antigen latent membrane proteins, another CAR construct from Houston was tolerable and effective as adjuvant or re-induction therapy in patients with EBV-associated lymphoma<sup><a href="#ref-57">57</a></sup>. Another construct is targeting CD19 in the HL tumor microenvironment and on circulating CD19-positive HRS precursor cells and among four patients treated, one CR and one PR with consecutive progressive disease were observed<sup><a href="#ref-58">58</a></sup>. Promising preclinical activity was additionally reported for CARs targeting CD123 to affect both the HRS cells and microenvironment<sup><a href="#ref-59">59</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e533>Selected ongoing first-line trials</h2><p class="" id=d19108e536>While numerous phase II trials investigate various combinations of novel agents with conventional chemotherapy or each other in rrHL, the trial landscape is scarcer in the first-line setting. Investigating innovative therapies for these patients is challenging since current approaches bear mostly excellent long-term outcome. Decreasing intensity within the controlled setting of prospective trials previously resulted in significantly inferior disease control. However, an impaired OS was not reported and this was likely due to effective salvage therapies and no increase in late reoccurrences of HL observed so far<sup><a href="#ref-4">4</a>,<a href="#ref-31">31</a>,<a href="#ref-60">60</a></sup>.</p><p class="" id=d19108e549>To improve results in patients with early-stage unfavorable HL without exposing them to the toxicity of 2+2, two ongoing investigator-initiated phase II trials investigate innovative strategies. In the randomized GHSG NIVAHL trial, patients receive the combination of nivolumab and AVD as either 4xNivo-AVD or 4x nivolumab + 2xNivo-AVD + 2xAVD, each followed by consolidative 30 Gy IS-RT (ClinicalTrials.gov Identifier: NCT03004833). A combination of AVD with BV is investigated in a US-based trial with a focus on consolidative RT (ClinicalTrials.gov Identifier: NCT01868451). Assigned to one of four different cohorts, patients will receive 30 Gy IS-RT, 20 Gy IS-RT, 30.6 Gy consolidation volume RT, or no RT if PET negativity is achieved after 4xBV-AVD.</p><p class="" id=d19108e552>In advanced-stage disease, the multinational randomized phase III trial HD21 is comparing a modified BEACOPP-regimen incorporating BV, dacarbazine, and dexamethasone instead of bleomycin, vincristine, procarbazine, and prednisolone (BRECADD)<sup><a href="#ref-61">61</a></sup> versus BEACOPP<sub>escalated</sub>. The trial is aiming to show non-inferiority in terms of efficacy and superiority in terms of treatment-related morbidity (ClinicalTrials.gov Identifier: NCT02661503), thereby better balancing risk and benefits of an intensified first-line treatment. As the CHOP (cyclophosphamide, doxorubicin, prednisone, and vincristine) regimen is well tolerated in elderly patients with non-HL<sup><a href="#ref-62">62</a></sup>, the combination of BV with a CHOP-like regimen is being investigated in the phase-II B-CAP trial for elderly patients with advanced-stage HL (ClinicalTrials.gov Identifier: NCT02191930).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e570>Future perspectives</h2><p class="" id=d19108e573>First-line treatment of HL with multi-agent chemotherapy and often consolidative RT is well established and results in cure in the majority of patients eligible for intensive therapies. Nevertheless, prognosis is less favorable in frail or older patients, and long-term side effects such as second cancers, organ damage, or fatigue as well as rrHL constitute considerable sequelae. The approval of modern drugs such as BV, nivolumab, and pembrolizumab for rrHL allow ongoing and future research to develop at least equally effective but less toxic therapies. Increasing understanding of PET imaging also as a potential prognostic marker by assessment of the metabolic tumor volume allows increased patient stratification and individualization of the therapeutic sequence. A growing understanding of the underlying biology, as well as the possibility to evaluate genetic alterations and monitor activity of disease by cell-free tumor DNA, additionally helps in doing so. From this point forward, it is crucial to keep in mind the currently achieved outcomes with conventional approaches. Carefully refining HL therapy meeting the needs and primary goals of affected patients is challenging, and ideally changes in clinical routine should be informed by evidence from randomized phase III trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19108e579>Abbreviations</h2><p class="" id=d19108e582>ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; alloSCT, allogeneic stem cell transplantation; AVD, doxorubicin, vinblastine, dacarbazine; BEACOPP<sub>escalated</sub>, bleomycin, etoposide, doxorubicin, cyclophosphamide, vinblastine, procarbazine, prednisone; BRECADD, brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; BV, brentuximab vedotin; CAR, chimeric antigen receptor; CHOP, cyclophosphamide, doxorubicin, prednisone, and vincristine; CR, complete response; CRR, complete response rate; EBV, EpsteinBarr virus; EN, extra-nodal; HL, Hodgkin lymphoma; HRS, Hodgkin and ReedSternberg; IF-RT, involved-field radiation therapy; IN-RT, involved-node radiation therapy; IS-RT, involved-site radiation therapy; LMM, large mediastinal mass; MHC, major histocompatibility class; Nivo, nivolumab; ORR, overall response rate; OS, overall survival; PD-1, programmed-death receptor 1; PD-L1, programmed-death receptor 1 ligand; PET, <sup>18</sup>F-FDG positron emission tomography; PFS, progression-free survival; PR, partial remission; RF, risk factor; rrHL, relapsed or refractory Hodgkin lymphoma; RT, radiation therapy; SCT, stem cell transplantation; SD, stabilization of disease</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d19108e1 class=n-a></a><h2 class=main-title id=d19321>Grant information</h2><p>The author(s) declare that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d19108e595 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d19519>References</h2><div class="section ref-list"><a name=d19108e595 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d19108e602 class=n-a></a>Robert Koch Institut: Krebs in Deutschland, ICD-10 C81 Morbus Hodgkin. 2013; 112115. <a target=xrefwindow id=d19108e604 href="https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/kid_2017_c81_morbus_hodgkin.pdf?__blob=publicationFile">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d19108e613 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. <i>CA Cancer J Clin.</i> 2015; <b>65</b>(1): 529. <a target=xrefwindow id=d19108e621 href="http://www.ncbi.nlm.nih.gov/pubmed/25559415">PubMed Abstract </a> | <a target=xrefwindow id=d19108e624 href="https://doi.org/10.3322/caac.21254">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d19108e633 class=n-a></a>Brckelmann PJ, Angelopoulou MK, Vassilakopoulos TP: Prognostic factors in Hodgkin lymphoma. <i>Semin Hematol.</i> 2016; <b>53</b>(3): 15564. <a target=xrefwindow id=d19108e641 href="http://www.ncbi.nlm.nih.gov/pubmed/27496306">PubMed Abstract </a> | <a target=xrefwindow id=d19108e644 href="https://doi.org/10.1053/j.seminhematol.2016.05.003">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725290094"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e653 class=n-a></a>Behringer K, Goergen H, Hitz F, <i> et al.</i>: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet.</i> 2015; <b>385</b>(9976): 141827. <a target=xrefwindow id=d19108e664 href="http://www.ncbi.nlm.nih.gov/pubmed/25539730">PubMed Abstract </a> | <a target=xrefwindow id=d19108e667 href="https://doi.org/10.1016/S0140-6736(14)61469-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725290094">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d19108e680 class=n-a></a>von Tresckow B, Pltschow A, Fuchs M, <i> et al.</i>: Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. <i>J Clin Oncol.</i> 2012; <b>30</b>(9): 90713. <a target=xrefwindow id=d19108e691 href="http://www.ncbi.nlm.nih.gov/pubmed/22271480">PubMed Abstract </a> | <a target=xrefwindow id=d19108e694 href="https://doi.org/10.1200/JCO.2011.38.5807">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732029166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e704 class=n-a></a>Borchmann P, Goergen H, Kobe C, <i> et al.</i>: PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. <i>Lancet.</i> 2018; <b>390</b>(10114): 2790802. <a target=xrefwindow id=d19108e715 href="http://www.ncbi.nlm.nih.gov/pubmed/29061295">PubMed Abstract </a> | <a target=xrefwindow id=d19108e718 href="https://doi.org/10.1016/S0140-6736(17)32134-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732029166">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d19108e731 class=n-a></a>Sasse S, Brckelmann PJ, Goergen H, <i> et al.</i>: Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. <i>J Clin Oncol.</i> 2017; <b>35</b>(18): 19992007. <a target=xrefwindow id=d19108e742 href="http://www.ncbi.nlm.nih.gov/pubmed/28418763">PubMed Abstract </a> | <a target=xrefwindow id=d19108e745 href="https://doi.org/10.1200/JCO.2016.70.9410">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d19108e754 class=n-a></a>Josting A, Mller H, Borchmann P, <i> et al.</i>: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. <i>J Clin Oncol.</i> 2010; <b>28</b>(34): 507480. <a target=xrefwindow id=d19108e765 href="http://www.ncbi.nlm.nih.gov/pubmed/20975066">PubMed Abstract </a> | <a target=xrefwindow id=d19108e768 href="https://doi.org/10.1200/JCO.2010.30.5771">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d19108e777 class=n-a></a>Younes A, Santoro A, Shipp M, <i> et al.</i>: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(9): 128394. <a target=xrefwindow id=d19108e788 href="http://www.ncbi.nlm.nih.gov/pubmed/27451390">PubMed Abstract </a> | <a target=xrefwindow id=d19108e791 href="https://doi.org/10.1016/S1470-2045(16)30167-X">Publisher Full Text </a> | <a target=xrefwindow id=d19108e795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5541855">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14263968"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e804 class=n-a></a>Younes A, Gopal AK, Smith SE, <i> et al.</i>: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J Clin Oncol.</i> 2012; <b>30</b>(18): 21839. <a target=xrefwindow id=d19108e815 href="http://www.ncbi.nlm.nih.gov/pubmed/22454421">PubMed Abstract </a> | <a target=xrefwindow id=d19108e818 href="https://doi.org/10.1200/JCO.2011.38.0410">Publisher Full Text </a> | <a target=xrefwindow id=d19108e822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3646316">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14263968">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727550687"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e835 class=n-a></a>Chen R, Zinzani PL, Fanale MA, <i> et al.</i>: Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>J Clin Oncol.</i> 2017; <b>35</b>(19): 212532. <a target=xrefwindow id=d19108e846 href="http://www.ncbi.nlm.nih.gov/pubmed/28441111">PubMed Abstract </a> | <a target=xrefwindow id=d19108e849 href="https://doi.org/10.1200/JCO.2016.72.1316">Publisher Full Text </a> | <a target=xrefwindow id=d19108e853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5791843">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727550687">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d19108e867 class=n-a></a>Ng AK: Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects. <i>Blood.</i> 2014; <b>124</b>(23): 33739. <a target=xrefwindow id=d19108e875 href="http://www.ncbi.nlm.nih.gov/pubmed/25428219">PubMed Abstract </a> | <a target=xrefwindow id=d19108e878 href="https://doi.org/10.1182/blood-2014-05-579193">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726037659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e887 class=n-a></a>Schaapveld M, Aleman BM, van Eggermond AM, <i> et al.</i>: Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. <i>N Engl J Med.</i> 2015; <b>373</b>(26): 2499511. <a target=xrefwindow id=d19108e898 href="http://www.ncbi.nlm.nih.gov/pubmed/26699166">PubMed Abstract </a> | <a target=xrefwindow id=d19108e901 href="https://doi.org/10.1056/NEJMoa1505949">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726037659">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726728706"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e914 class=n-a></a>Kreissl S, Mueller H, Goergen H, <i> et al.</i>: Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. <i>Lancet Oncol.</i> 2016; <b>17</b>(10): 145362. <a target=xrefwindow id=d19108e925 href="http://www.ncbi.nlm.nih.gov/pubmed/27612583">PubMed Abstract </a> | <a target=xrefwindow id=d19108e928 href="https://doi.org/10.1016/S1470-2045(16)30093-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726728706">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d19108e941 class=n-a></a>Bhakta N, Liu Q, Yeo F, <i> et al.</i>: Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study. <i>Lancet Oncol.</i> 2016; <b>17</b>(9): 132534. <a target=xrefwindow id=d19108e952 href="http://www.ncbi.nlm.nih.gov/pubmed/27470081">PubMed Abstract </a> | <a target=xrefwindow id=d19108e955 href="https://doi.org/10.1016/S1470-2045(16)30215-7">Publisher Full Text </a> | <a target=xrefwindow id=d19108e959 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5029267">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d19108e968 class=n-a></a>Borchmann S, Engert A, Bll B: Hodgkin lymphoma in elderly patients. <i>Curr Opin Oncol.</i> 2018; <b>30</b>(5): 30816. <a target=xrefwindow id=d19108e976 href="http://www.ncbi.nlm.nih.gov/pubmed/29994901">PubMed Abstract </a> | <a target=xrefwindow id=d19108e979 href="https://doi.org/10.1097/CCO.0000000000000464">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d19108e988 class=n-a></a>Bll B, Grgen H, Fuchs M, <i> et al.</i>: ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. <i>J Clin Oncol.</i> 2013; <b>31</b>(12): 15229. <a target=xrefwindow id=d19108e999 href="http://www.ncbi.nlm.nih.gov/pubmed/23509310">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1002 href="https://doi.org/10.1200/JCO.2012.45.4181">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726221128"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1012 class=n-a></a>Swerdlow SH, Campo E, Pileri SA, <i> et al.</i>: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood.</i> 2016; <b>127</b>(20): 237590. <a target=xrefwindow id=d19108e1023 href="http://www.ncbi.nlm.nih.gov/pubmed/26980727">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1026 href="https://doi.org/10.1182/blood-2016-01-643569">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1030 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4874220">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726221128">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d19108e1043 class=n-a></a>Yamamoto R, Nishikori M, Kitawaki T, <i> et al.</i>: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. <i>Blood.</i> 2008; <b>111</b>(6): 32204. <a target=xrefwindow id=d19108e1054 href="http://www.ncbi.nlm.nih.gov/pubmed/18203952">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1057 href="https://doi.org/10.1182/blood-2007-05-085159">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d19108e1066 class=n-a></a>Roemer MG, Advani RH, Ligon AH, <i> et al.</i>: <i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>J Clin Oncol.</i> 2016; <b>34</b>(23): 26907. <a target=xrefwindow id=d19108e1084 href="http://www.ncbi.nlm.nih.gov/pubmed/27069084">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1087 href="https://doi.org/10.1200/JCO.2016.66.4482">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1090 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019753">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d19108e1099 class=n-a></a>Green MR, Rodig S, Juszczynski P, <i> et al.</i>: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. <i>Clin Cancer Res.</i> 2012; <b>18</b>(6): 16118. <a target=xrefwindow id=d19108e1110 href="http://www.ncbi.nlm.nih.gov/pubmed/22271878">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1113 href="https://doi.org/10.1158/1078-0432.CCR-11-1942">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1117 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3321508">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d19108e1126 class=n-a></a>Reichel J, Chadburn A, Rubinstein PG, <i> et al.</i>: Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood.</i> 2015; <b>125</b>(7): 106172. <a target=xrefwindow id=d19108e1137 href="http://www.ncbi.nlm.nih.gov/pubmed/25488972">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1140 href="https://doi.org/10.1182/blood-2014-11-610436">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d19108e1149 class=n-a></a>Muenst S, Hoeller S, Dirnhofer S, <i> et al.</i>: Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. <i>Hum Pathol.</i> 2009; <b>40</b>(12): 171522. <a target=xrefwindow id=d19108e1160 href="http://www.ncbi.nlm.nih.gov/pubmed/19695683">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1163 href="https://doi.org/10.1016/j.humpath.2009.03.025">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732682886"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1173 class=n-a></a>Vari F, Arpon D, Keane C, <i> et al.</i>: Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. <i>Blood.</i> 2018; <b>131</b>(16): 180919. <a target=xrefwindow id=d19108e1184 href="http://www.ncbi.nlm.nih.gov/pubmed/29449276">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1187 href="https://doi.org/10.1182/blood-2017-07-796342">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1191 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5922274">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732682886">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d19108e1204 class=n-a></a>Steidl C, Lee T, Shah SP, <i> et al.</i>: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. <i>N Engl J Med.</i> 2010; <b>362</b>(10): 87585. <a target=xrefwindow id=d19108e1215 href="http://www.ncbi.nlm.nih.gov/pubmed/20220182">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1218 href="https://doi.org/10.1056/NEJMoa0905680">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1222 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2897174">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733419988"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1231 class=n-a></a>Cader FZ, Schackmann RCJ, Hu X, <i> et al.</i>: Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood.</i> 2018; <b>132</b>(8): 82536. <a target=xrefwindow id=d19108e1245 href="http://www.ncbi.nlm.nih.gov/pubmed/29880615">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1249 href="https://doi.org/10.1182/blood-2018-04-843714">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1252 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6107878">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733419988">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d19108e1265 class=n-a></a>Vandenberghe P, Wlodarska I, Tousseyn T, <i> et al.</i>: Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study. <i>Lancet Haematol.</i> 2015; <b>2</b>(2): e5565. <a target=xrefwindow id=d19108e1276 href="http://www.ncbi.nlm.nih.gov/pubmed/26687610">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1279 href="https://doi.org/10.1016/S2352-3026(14)00039-8">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d19108e1288 class=n-a></a>Klimm B, Goergen H, Fuchs M, <i> et al.</i>: Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. <i>Ann Oncol.</i> 2013; <b>24</b>(12): 30706. <a target=xrefwindow id=d19108e1299 href="http://www.ncbi.nlm.nih.gov/pubmed/24148816">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1302 href="https://doi.org/10.1093/annonc/mdt413">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d19108e1311 class=n-a></a>Engert A, Franklin J, Eich HT, <i> et al.</i>: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. <i>J Clin Oncol.</i> 2007; <b>25</b>(23): 3495502. <a target=xrefwindow id=d19108e1322 href="http://www.ncbi.nlm.nih.gov/pubmed/17606976">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1325 href="https://doi.org/10.1200/JCO.2006.07.0482">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1047597"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1335 class=n-a></a>Noordijk EM, Carde P, Dupouy N, <i> et al.</i>: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. <i>J Clin Oncol.</i> 2006; <b>24</b>(19): 312835. <a target=xrefwindow id=d19108e1346 href="http://www.ncbi.nlm.nih.gov/pubmed/16754934">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1349 href="https://doi.org/10.1200/JCO.2005.05.2746">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1047597">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4844956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1362 class=n-a></a>Engert A, Pltschow A, Eich HT, <i> et al.</i>: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. <i>N Engl J Med.</i> 2010; <b>363</b>(7): 64052. <a target=xrefwindow id=d19108e1373 href="http://www.ncbi.nlm.nih.gov/pubmed/20818855">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1376 href="https://doi.org/10.1056/NEJMoa1000067">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4844956">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d19108e1389 class=n-a></a>Specht L, Yahalom J, Illidge T, <i> et al.</i>: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). <i>Int J Radiat Oncol Biol Phys.</i> 2014; <b>89</b>(4): 85462. <a target=xrefwindow id=d19108e1400 href="http://www.ncbi.nlm.nih.gov/pubmed/23790512">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1403 href="https://doi.org/10.1016/j.ijrobp.2013.05.005">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d19108e1412 class=n-a></a>Hay AE, Klimm B, Chen BE, <i> et al.</i>: An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. <i>Ann Oncol.</i> 2013; <b>24</b>(12): 30659. <a target=xrefwindow id=d19108e1423 href="http://www.ncbi.nlm.nih.gov/pubmed/24121121">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1426 href="https://doi.org/10.1093/annonc/mdt389">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d19108e1435 class=n-a></a>Olszewski AJ, Shrestha R, Castillo JJ: Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. <i>J Clin Oncol.</i> 2015; <b>33</b>(6): 62533. <a target=xrefwindow id=d19108e1443 href="http://www.ncbi.nlm.nih.gov/pubmed/25584010">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1446 href="https://doi.org/10.1200/JCO.2014.58.7543">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d19108e1455 class=n-a></a>Radford J, Barrington S, Counsell N, <i> et al.</i>: Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts. 2012; <b>120</b>: 547. <a target=xrefwindow id=d19108e1463 href="https://www.epistemonikos.org/es/documents/1ea0263f9a65bd62e88d8d0eadfa818042242ebe">Reference Source</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727407786"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1473 class=n-a></a>Andr MPE, Girinsky T, Federico M, <i> et al.</i>: Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(16): 178694. <a target=xrefwindow id=d19108e1484 href="http://www.ncbi.nlm.nih.gov/pubmed/28291393">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1487 href="https://doi.org/10.1200/JCO.2016.68.6394">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727407786">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d19108e1500 class=n-a></a>Skoetz N, Trelle S, Rancea M, <i> et al.</i>: Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. <i>Lancet Oncol.</i> 2013; <b>14</b>(10): 94352. <a target=xrefwindow id=d19108e1511 href="http://www.ncbi.nlm.nih.gov/pubmed/23948348">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1514 href="https://doi.org/10.1016/S1470-2045(13)70341-3">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d19108e1523 class=n-a></a>Johnson P, Federico M, Kirkwood A, <i> et al.</i>: Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>N Engl J Med.</i> 2016; <b>374</b>(25): 241929. <a target=xrefwindow id=d19108e1534 href="http://www.ncbi.nlm.nih.gov/pubmed/27332902">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1537 href="https://doi.org/10.1056/NEJMoa1510093">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1541 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4961236">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d19108e1550 class=n-a></a>Casasnovas O, Brice P, Bouabdallah R, <i> et al.</i>: FINAL ANALYSIS OF THE AHL2011 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA. <i>EHA Learning Center.</i> 2018; 214504. <a target=xrefwindow id=d19108e1558 href="https://learningcenter.ehaweb.org/eha/2018/stockholm/214504/olivier.casasnovas.final.analysis.of.the.ahl2011.randomized.phase.iii.lysa.html?f=topic=1574*media=3">Reference Source</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d19108e1567 class=n-a></a>Chen R, Gopal AK, Smith SE, <i> et al.</i>: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood.</i> 2016; <b>128</b>(12): 15626. <a target=xrefwindow id=d19108e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/27432875">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1581 href="https://doi.org/10.1182/blood-2016-02-699850">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5034737">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d19108e1594 class=n-a></a>Borchmann P, Foss A, Dugosz-Danecka M, <i> et al.</i>: The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. <i>HemaSphere.</i> 2018; <b>2</b>(3): e52. <a target=xrefwindow id=d19108e1605 href="https://doi.org/10.1097/HS9.0000000000000052">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733368753"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1615 class=n-a></a>Adams HJA, Kwee TC: Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven. <i>Blood.</i> 2018; <b>132</b>(3): 33940. <a target=xrefwindow id=d19108e1623 href="http://www.ncbi.nlm.nih.gov/pubmed/29858234">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1626 href="https://doi.org/10.1182/blood-2018-04-845438">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733368753">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d19108e1639 class=n-a></a>Park SI, Olajide OA, Reddy NM, <i> et al.</i>: A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. <i>JCO.</i> 2016; <b>34</b>(15_suppl): 7508. <a target=xrefwindow id=d19108e1650 href="https://doi.org/10.1200/JCO.2016.34.15_suppl.7508">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733945723"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1659 class=n-a></a>Evens AM, Advani RH, Helenowski IB, <i> et al.</i>: Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>J Clin Oncol.</i> 2018; <b>36</b>(30): JCO2018790139. <a target=xrefwindow id=d19108e1670 href="http://www.ncbi.nlm.nih.gov/pubmed/30179569">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1673 href="https://doi.org/10.1200/JCO.2018.79.0139">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733945723">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732595799"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1686 class=n-a></a>Roemer MGM, Redd RA, Cader FZ, <i> et al.</i>: Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>J Clin Oncol.</i> 2018; <b>36</b>(10): 94250. <a target=xrefwindow id=d19108e1697 href="http://www.ncbi.nlm.nih.gov/pubmed/29394125">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1700 href="https://doi.org/10.1200/JCO.2017.77.3994">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1704 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5877802">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732595799">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732284902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1717 class=n-a></a>Herrera AF, Moskowitz AJ, Bartlett NL, <i> et al.</i>: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood.</i> 2018; <b>131</b>(11): 118394. <a target=xrefwindow id=d19108e1728 href="http://www.ncbi.nlm.nih.gov/pubmed/29229594">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1731 href="https://doi.org/10.1182/blood-2017-10-811224">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5855021">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732284902">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d19108e1748 class=n-a></a>Ramchandren R, Domenech ED, Rueda A, <i> et al.</i>: CHECKMATE 205 COHORT D: A PHASE 2 TRIAL OF NIVOLUMAB FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA. EHA Learning Center. 2018; <b>214507</b>. <a target=xrefwindow id=d19108e1756 href="https://learningcenter.ehaweb.org/eha/2018/stockholm/214507/radhakrishnan.ramchandren.checkmate.205.cohort.d.a.phase.2.trial.of.nivolumab.html?f=topic=1574*media=3">Reference Source</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d19108e1766 class=n-a></a>Moskowitz AJ, Hamlin PA Jr, Perales MA, <i> et al.</i>: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>J Clin Oncol.</i> 2013; <b>31</b>(4): 45660. <a target=xrefwindow id=d19108e1777 href="http://www.ncbi.nlm.nih.gov/pubmed/23248254">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1780 href="https://doi.org/10.1200/JCO.2012.45.3308">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3862960">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d19108e1793 class=n-a></a>Bll B, Borchmann P, Topp MS, <i> et al.</i>: Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. <i>Br J Haematol.</i> 2010; <b>148</b>(3): 4802. <a target=xrefwindow id=d19108e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/19863533">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1807 href="https://doi.org/10.1111/j.1365-2141.2009.07963.x">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d19108e1816 class=n-a></a>Younes A, Sureda A, Ben-Yehuda D, <i> et al.</i>: Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. <i>J Clin Oncol.</i> 2012; <b>30</b>(18): 2197203. <a target=xrefwindow id=d19108e1827 href="http://www.ncbi.nlm.nih.gov/pubmed/22547596">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1830 href="https://doi.org/10.1200/JCO.2011.38.1350">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727454561"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1839 class=n-a></a>Gopal AK, Fanale MA, Moskowitz CH, <i> et al.</i>: Phase II study of idelalisib, a selective inhibitor of PI3K, for relapsed/refractory classical Hodgkin lymphoma. <i>Ann Oncol.</i> 2017; <b>28</b>(5): 105763. <a target=xrefwindow id=d19108e1850 href="http://www.ncbi.nlm.nih.gov/pubmed/28327905">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1853 href="https://doi.org/10.1093/annonc/mdx028">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727454561">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d19108e1866 class=n-a></a>Younes A, Oki Y, Bociek RG, <i> et al.</i>: Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2011; <b>12</b>(13): 12228. <a target=xrefwindow id=d19108e1877 href="http://www.ncbi.nlm.nih.gov/pubmed/22033282">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1880 href="https://doi.org/10.1016/S1470-2045(11)70265-0">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5042214">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d19108e1893 class=n-a></a>Armand P, Zinzani PL, Collins GP, <i> et al.</i>: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. <i>Blood.</i> 2016; <b>128</b>: 3502. <a target=xrefwindow id=d19108e1904 href="http://www.bloodjournal.org/content/128/22/3502?sso-checked=true">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d19108e1914 class=n-a></a>Mear J-B, Nicolas-Virelizier E, Schiano JM, <i> et al.</i>: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA. EHA Learning Center. 2018; 214889. <a target=xrefwindow id=d19108e1919 href="https://learningcenter.ehaweb.org/eha/2018/stockholm/214889/jean-baptiste.mear.allogeneic.hematopoietic.stem.cell.transplantation.after.html?f=topic=1574*media=3">Reference Source</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728639693"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e1928 class=n-a></a>Ramos CA, Ballard B, Zhang H, <i> et al.</i>: Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. <i>J Clin Invest.</i> 2017; <b>127</b>(9): 346271. <a target=xrefwindow id=d19108e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/28805662">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1942 href="https://doi.org/10.1172/JCI94306">Publisher Full Text </a> | <a target=xrefwindow id=d19108e1946 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5669573">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728639693">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d19108e1959 class=n-a></a>Wang CM, Wu ZQ, Wang Y, <i> et al.</i>: Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. <i>Clin Cancer Res.</i> 2017; <b>23</b>(5): 115666. <a target=xrefwindow id=d19108e1970 href="http://www.ncbi.nlm.nih.gov/pubmed/27582488">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1973 href="https://doi.org/10.1158/1078-0432.CCR-16-1365">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d19108e1982 class=n-a></a>Bollard CM, Gottschalk S, Torrano V, <i> et al.</i>: Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. <i>J Clin Oncol.</i> 2014; <b>32</b>(8): 798808. <a target=xrefwindow id=d19108e1993 href="http://www.ncbi.nlm.nih.gov/pubmed/24344220">PubMed Abstract </a> | <a target=xrefwindow id=d19108e1996 href="https://doi.org/10.1200/JCO.2013.51.5304">Publisher Full Text </a> | <a target=xrefwindow id=d19108e2000 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3940538">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d19108e2009 class=n-a></a>Svoboda J, Rheingold SR, Gill SI, <i> et al.</i>: Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL). <i>Blood.</i> 2017; <b>130</b>: 653653. </span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d19108e2027 class=n-a></a>Ruella M, Klichinsky M, Kenderian SS, <i> et al.</i>: Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. <i>Cancer Discov.</i> 2017; <b>7</b>(10): 115467. <a target=xrefwindow id=d19108e2038 href="http://www.ncbi.nlm.nih.gov/pubmed/28576927">PubMed Abstract </a> | <a target=xrefwindow id=d19108e2041 href="https://doi.org/10.1158/2159-8290.CD-16-0850">Publisher Full Text </a> | <a target=xrefwindow id=d19108e2045 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5628114">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d19108e2055 class=n-a></a>Brckelmann PJ, Goergen H, Kohnhorst C, <i> et al.</i>: Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. <i>J Clin Oncol.</i> 2017; <b>35</b>(13): 144450. <a target=xrefwindow id=d19108e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/28240973">PubMed Abstract </a> | <a target=xrefwindow id=d19108e2069 href="https://doi.org/10.1200/JCO.2016.71.3289">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732115130"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19108e2078 class=n-a></a>Eichenauer DA, Pltschow A, Kreissl S, <i> et al.</i>: Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. <i>Lancet Oncol.</i> 2017; <b>18</b>(12): 16807. <a target=xrefwindow id=d19108e2089 href="http://www.ncbi.nlm.nih.gov/pubmed/29133014">PubMed Abstract </a> | <a target=xrefwindow id=d19108e2092 href="https://doi.org/10.1016/S1470-2045(17)30696-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732115130">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d19108e2105 class=n-a></a>Kolstad A, Nome O, Delabie J, <i> et al.</i>: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. <i>Leuk Lymphoma.</i> 2007; <b>48</b>(3): 5706. <a target=xrefwindow id=d19108e2116 href="http://www.ncbi.nlm.nih.gov/pubmed/17454601">PubMed Abstract </a> | <a target=xrefwindow id=d19108e2119 href="https://doi.org/10.1080/10428190601126610">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1786.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1786.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> German Hodgkin Study Group and Department I of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany<br/> <p> <div class=margin-bottom> Paul J. Br&ouml;ckelmann <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Boris B&ouml;ll <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1786/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 Nov 2018, 7:1786 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.16077.1">https://doi.org/10.12688/f1000research.16077.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Brckelmann PJ and Bll B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=17557 data-id=16077 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16077.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1786/v1/pdf?article_uuid=e19c96bb-76fa-401a-8605-33d1526390a8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.16077.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Brckelmann PJ and Bll B. Moving things forward in Hodgkin lymphoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1786 (<a href="https://doi.org/10.12688/f1000research.16077.1" target=_blank>https://doi.org/10.12688/f1000research.16077.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=16077 id=mobile-track-article-signin-16077 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16077?target=/articles/7-1786.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17557 /> <input name=articleId type=hidden value=16077 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Zs&oacute;fia Milt&eacute;nyi</strong>, Institution of Internal Medicine, Department of Hematology, University of Debrecen, Hungary </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephen Ansell</strong>, Department of Hematology, Mayo Clinic in Rochester, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1786.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1786.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=41551-40433></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=41549-40432></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1786/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 Nov 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Zs&oacute;fia Milt&eacute;nyi</strong>, Institution of Internal Medicine, Department of Hematology, University of Debrecen, Hungary </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephen Ansell</strong>, Department of Hematology, Mayo Clinic in Rochester, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1786.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1786/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Moving things forward in Hodgkin lymphoma".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1786/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1786/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1786/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Brckelmann PJ and Bll B');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1786/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1786",
            templates : {
                twitter : "Moving things forward in Hodgkin lymphoma. Brckelmann PJ and Bll B, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1786/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Moving things forward in Hodgkin lymphoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Moving things forward in Hodgkin lymphoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/16077/17557")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "17557");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "40432": 0,
                           "40433": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "99eac794-4589-4506-b0ac-305ef5de1d5f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1786.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1786.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1786.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1786.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1786.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>